D. Geoffrey Vince, PhD, is Executive Director of Innovations at Cleveland Clinic. He also holds The Virginia Lois Kennedy Chair in Biomedical Engineering and Applied Therapeutics and chairs the Department of Biomedical Engineering (BME), Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
In his role as Executive Director of Innovations, Dr. Vince is aligning Cleveland Clinic’s technology development strategies with scientific and research priorities—including unprecedented growth in data and computing sciences—to accelerate the development of new treatments and drugs. He is also capitalizing on Cleveland Clinic’s innovative culture to build strategic partnerships and alliances with industry to drive revenue growth through commercialization of intellectual property, which will help fuel medical advances and economic growth in Northeast Ohio.
Dr. Vince obtained his PhD in biomedical engineering from the University of Liverpool in 1989. He came to Cleveland Clinic BME as a Postdoctoral Research Fellow in 1992, rising to Associate Staff by 2003.
In BME, Dr. Vince and colleagues invented a new methodology for imaging the interior of coronary arteries using intravascular ultrasound. This methodology, “Virtual Histology™,” was patented and later licensed to Volcano Therapeutics (now Volcano Corp.).
In 2005, Dr. Vince left Cleveland Clinic to join Volcano’s Cleveland office as Director of Research. In 2006, he became Vice-President of Clinical and Advanced R&D, moving to Volcano’s headquarters in San Diego, California. His invention is now a product of some 7,000 units worldwide. (Volcano was purchased by Philips in 2015.) Dr. Vince returned to Cleveland in 2011 to become Chair of Cleveland Clinic BME.
Dr. Vince is currently Principal Investigator of the Cleveland Clinic site for a grant awarded under the NIH Centers for Accelerated Innovations (NCAI) program, an initiative of the NHLBI/NIH. He is an inventor on more than 60 patents or patent applications in the United States and worldwide. More recently, Dr. Vince has been working with colleagues at Cleveland Clinic to develop a breathalyzer for simple, non-invasive, early detection of COVID-19.